Abcuro and ImaginAb are highlighting the results of a study using the Immuno-PET radiotracer to show that CD8+ T-cells are present throughout the skeletal muscle system in patients with inclusion body myositis (IBM).
ImaginAb's antibody-fragment imaging technology offers a more comprehensive view of T-cell infiltration than muscle biopsies provide. The Immuno-PET technology binds to and lights up the specific immune cell type that is central to the etiology of IBM.
Viewing the entire spectrum of skeletal muscle allowed Abcuro to assess the presence of CD8+ T-cells prior to dosing patients with the therapeutic agent ABC008, according to the results.
